Zolidronic acid and Charcot's foot

The objective of this study was to investigate the role of zoledronic acid in the treatment of diabetic Charcot foot. We enrolled 8 type 2 diabetic patients with Charcot neuroarthropathy. All our patients had a complete clinical examination and a podiatric examination. The stage of the neuroathropathy was evaluated. Zolidronic acid was administered to all patients at a dose of 4 mg/100 ml, as an intravenous infusion. We then evaluated the effectiveness of the treatment clinically and radiographically. The mean age of the patients was 61.4 years [55-64]. The mean time to onset of foot pain was 18.3 years [17-20]. The midfoot involvement was bilateral in 6 patients and unilateral in the other two. The neuroarthropathy was in the state phase of the Eichonholtz classification in 7 patients and in the acute phase in the 8th patient. Standard radiographs of the feet were all abnormal. We noted a disappearance of pain in 6 patients, an improvement of pain in one patient (VAS: decreased by 30%) and a persistence of mechanical pain in 1 patient (VAS 5).

Autorentext

Boussaid SoumayaAsistente de reumatología, departamento de reumatología; Hospital La Rabta; Túnez; TúnezDiplomado en medicina deportiva, ecografía osteoarticular, podología, patología de la columna vertebral, tratamiento del dolor e imagen del sistema musculoesquelético.